Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 186 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 6758
Sealed predictions
- HOXB3 in dopamine neurons, braak+0.26 (p 0.502) → -0.06 (p 0.877)receipt 6765
Swarm cases
receipt 6765: HOXB3 in dopamine neurons, braak
- power
- full sample +0.08 (p 0.754, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.23 (p 0.369, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.17 (p 0.509, n 18). could be the mix.
- skeptic
- leave-one-out range -0.06 to +0.19, sign flips 4; without severely affected donors +0.08 (p 0.754, n 18). fragile.
- cell type
- strongest in OPCs: -0.59 (p 0.0092, n 18) vs +0.08 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for HOXB3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up HOXB3 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.36 p 0.197 (needs p < 3.1e-4)
Receipts
loading the receipts